Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 7/20 | 0.41 |
| ▸ | F13A1 | P00488 | 5/20 | 0.41 |
| ▸ | TGM1 | P22735 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626288 | 0.82 | LMNA (0.60) | LMNANPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12655883 | 0.81 | HCRTR1 (0.50) | GPR119NAMPTALDH1A1 | |
| SCHEMBL12626285 | 0.78 | ALDH1A1 (0.56) | LMNANPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12626996 | 0.78 | GFER (0.47) | GPR119NAMPTTGM2F13A1TGM1 | |
| SCHEMBL20365008 | 0.75 | LMNA (0.52) | LMNANPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12626325 | 0.73 | LIMK2 (0.44) | GPR119NAMPTTGM2STS | |
| SCHEMBL23411856 | 0.72 | GPR119 (0.55) | GPR119LMNANPC1ALDH1A1MAPT | |
| SCHEMBL26372776 | 0.71 | GPR119 (0.54) | GPR119NPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15426422 | 0.71 | HCRTR1 (0.51) | GPR119ALDH1A1MEN1KMT2A | |
| SCHEMBL14400848 | 0.70 | MMP1 (0.56) | GPR119LMNATGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | GPR119 2527/4885LMNA 216/4885NAMPT 3322/4885 |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | GPR119 2527/4885LMNA 216/4885NAMPT 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.